XML 40 R28.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Acquisitions (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
BioFlex And NTM Acquisition |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | The components and estimated allocation of the purchase price consist of the following (amounts in thousands):
Cash and cash equivalents |  | $ | 2,870 |
Accounts receivable |  |  | 1,408 |
Inventory |  |  | 741 |
Prepaid expenses and other current assets |  |  | 126 |
Property and equipment |  |  | 34 |
Operating lease right of use asset |  |  | 1,034 |
Customer relationships |  |  | 13,240 |
Developed technology |  |  | 3,540 |
Trademark and tradename |  |  | 310 |
Non-competition agreements |  |  | 60 |
Goodwill |  |  | 10,180 |
Long term deferred tax asset |  |  | 111 |
Accounts payable |  |  | (224 | )
Accrued liabilities |  |  | (574 | )
Operating lease liability |  |  | (1,030 | )
Operating lease liability, long-term |  |  | (3 | )
Fair value of net assets acquired |  | $ | 31,823 |
Schedule of Identified Intangible Assets and Estimated Useful Lives | The following table sets forth the components of the identified intangible assets associated with the NTM Acquisition and their estimated useful lives:
|  | Useful life |  | Fair Value |
|  |  |  | (Amounts in thousands) |
Customer relationships |  | 10 years |  | $ | 13,240 |
Developed technology |  | 11 years |  |  | 3,540 |
Trademark and tradename |  | 15 years |  |  | 310 |
Non-competition agreements |  | 3 years |  |  | 60 |
|  |  |  | $ | 17,150 |
Avitide Inc. |
Schedule of Business Combination Consideration Transferred | Total consideration transferred is as follows (amounts in thousands):
Cash consideration |  | $ | 74,962 |
Equity consideration |  |  | 82,968 |
Contingent consideration - earnout |  |  | 88,373 |
Fair value of net assets acquired |  | $ | 246,303 |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | The components and estimated allocation of the purchase price consist of the following (amounts in thousands):
Cash and cash equivalents |  | $ | 572 |
Accounts receivable |  |  | 228 |
Inventory |  |  | 332 |
Prepaid expenses and other current assets |  |  | 114 |
Property and equipment |  |  | 1,862 |
Operating lease right of use asset |  |  | 3,648 |
Customer relationships |  |  | 24,580 |
Developed technology |  |  | 20,650 |
Trademark and tradename |  |  | 1,210 |
Non-competition agreements |  |  | 210 |
Goodwill |  |  | 199,245 |
Accounts payable |  |  | (215 | )
Accrued liabilities |  |  | (2,183 | )
Operating lease liability |  |  | (698 | )
Operating lease liability, long-term |  |  | (2,950 | )
Long term deferred tax liability |  |  | (244 | )
Other liabilities |  |  | (58 | )
Fair value of net assets acquired |  | $ | 246,303 |
Schedule of Identified Intangible Assets and Estimated Useful Lives | The following table sets forth the components of the identified intangible assets associated with the Avitide Acquisition and their estimated useful lives:
|  | Useful life |  | Fair Value |
|  |  |  | (Amounts in thousands) |
Customer relationships |  | 13 years |  | $ | 24,580 |
Developed technology |  | 15 years |  |  | 20,650 |
Trademark and tradename |  | 18 years |  |  | 1,210 |
Non-competition agreements |  | 3 years |  |  | 210 |
|  |  |  | $ | 46,650 |
Polymem S.A. |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | The components and estimated allocation of the purchase price consist of the following (amounts in thousands):
Cash and cash equivalents |  | $ | 353 |
Net working capital (excluding cash and inventory step-up) |  |  | 414 |
Inventory step-up |  |  | 543 |
Operating lease right of use assets |  |  | 1,424 |
Property and equipment |  |  | 3,145 |
Other assets |  |  | 41 |
Developed technology |  |  | 8,274 |
Trademark and tradenames |  |  | 510 |
Non-compete agreements |  |  | 312 |
Goodwill |  |  | 35,680 |
Operating lease liability |  |  | (1,253 | )
Long term deferred tax liability |  |  | (2,327 | )
Other long-term liabilities |  |  | (143 | )
Fair value of net assets acquired |  | $ | 46,973 |
Schedule of Identified Intangible Assets and Estimated Useful Lives | The following table sets forth the components of the identified intangible assets associated with the Polymem Acquisition and their estimated useful lives:
|  | Useful life |  | Fair Value |
|  |  |  | (Amounts in thousands) |
Developed technology |  | 13 years |  | $ | 8,274 |
Trademark and tradename |  | 14 years |  |  | 510 |
Non-competition agreements |  | 5 years |  |  | 312 |
|  |  |  | $ | 9,096 |
ARTeSYN Biosolutions |
Schedule of Business Combination Consideration Transferred | Total consideration transferred is as follows (amounts in thousands):
Cash consideration |  | $ | 130,713 |
Equity consideration |  |  | 69,422 |
Contingent consideration |  |  | 1,548 |
Settlement of preexisting liabilities |  |  | 2,310 |
Fair value of net assets acquired |  | $ | 203,993 |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | The components and estimated allocation of the purchase price consists of the following amounts (amounts in thousands):
Cash and cash equivalents |  | $ | 2,982 |
Accounts receivable |  |  | 4,811 |
Inventory |  |  | 8,592 |
Prepaid expenses and other current assets |  |  | 5,561 |
Property and equipment |  |  | 1,836 |
Operating lease right of use asset |  |  | 1,611 |
Other noncurrent assets |  |  | 26 |
Customer relationships |  |  | 38,400 |
Developed technology |  |  | 27,060 |
Trademark and tradename |  |  | 1,630 |
Non-competition agreements |  |  | 300 |
Goodwill |  |  | 128,598 |
Accounts payable |  |  | (2,251 | )
Accrued liabilities |  |  | (8,706 | )
Deferred revenue |  |  | (3,583 | )
Deferred tax liabilities, net |  |  | (1,240 | )
Notes payable |  |  | (24 | )
Operating lease liability |  |  | (417 | )
Operating lease liability, long-term |  |  | (1,193 | )
Fair value of net assets acquired |  | $ | 203,993 |
Schedule of Identified Intangible Assets and Estimated Useful Lives | The following table sets forth the components of the identified intangible assets associated with the ARTeSYN Acquisition and their estimated useful lives:
|  | Useful life |  | Fair Value |
|  |  |  | (Amounts in thousands) |
Customer relationships |  | 17 years |  | $ | 38,400 |
Developed technology |  | 15 years |  |  | 27,060 |
Trademark and tradename |  | 21 years |  |  | 1,630 |
Non-competition agreements |  | 3 years |  |  | 300 |
|  |  |  | $ | 67,390 |
Non Metallic Solutions |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | The components and allocation of the purchase price consist of the following (amounts in thousands):
Cash and cash equivalents |  | $ | 1,163 |
Accounts receivable |  |  | 415 |
Inventory |  |  | 334 |
Prepaid expenses and other current assets |  |  | 13 |
Property and equipment |  |  | 73 |
Operating lease right of use asset |  |  | 194 |
Customer relationships |  |  | 6,370 |
Developed technology |  |  | 1,810 |
Trademark and tradename |  |  | 190 |
Non-competition agreements |  |  | 90 |
Goodwill |  |  | 6,713 |
Deferred tax assets |  |  | 24 |
Accounts payable |  |  | (96 | )
Accrued liabilities |  |  | (999 | )
Operating lease liability |  |  | (136 | )
Operating lease liability, long-term |  |  | (59 | )
Fair value of net assets acquired |  | $ | 16,099 |
Schedule of Identified Intangible Assets and Estimated Useful Lives | The following table sets forth the components of the identified intangible assets associated with the NMS Acquisition and their estimated useful lives:
|  | Useful life |  | Fair Value |
|  |  |  | (Amounts in thousands) |
Customer relationships |  | 14 years |  | $ | 6,370 |
Developed technology |  | 12 years |  |  | 1,810 |
Trademark and tradename |  | 15 years |  |  | 190 |
Non-competition agreements |  | 3 years |  |  | 90 |
|  |  |  | $ | 8,460 |

X
- Definition Tabular disclosure of business combination consideration transferred. + References No definition available. + Details
Name: | rgen_ScheduleOfBusinessCombinationConsiderationTransferredTableTextBlock
Namespace Prefix: | rgen_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472 + Details
Name: | us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rgen_BioflexAndNtmAcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rgen_AvitideIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rgen_PolymemSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rgen_ArtesynBiosolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rgen_NonMetallicSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |